Evaluation and management of the acutely dyspneic patient: the role of biomarkers
Authors:
- Alex HarrisonAHAlex Harrison
- Stanley AmundsonSAStanley Amundson
- 1 May 2005
- journal article
- research article
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 23 (3) , 371-378
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute DyspneaNew England Journal of Medicine, 2004
- Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non–ST-elevation myocardial infarctionJACC, 2003
- Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general populationJACC, 2003
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Acute Coronary Syndromes — Beyond Myocyte NecrosisNew England Journal of Medicine, 2001
- Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trialEuropean Heart Journal, 2000
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Assessing diagnosis in heart failure: which features are any use?QJM: An International Journal of Medicine, 1997
- Rapid renal clearance of immunoreactive canine plasma myoglobin.Circulation, 1982
- Natural history of pulmonary embolismProgress in Cardiovascular Diseases, 1975